基于15-PGDH抑制剂的知识和结构设计
Leela S Dodda1, Sebastien Campos2, David Ciccone1
1Nimbus Therapeutics, Boston, Massachusetts 02210, United States.
Journal of medicinal chemistry
|August 27, 2025
概括
抑制15- 前列腺素脱酶 (15-PGDH) 可以提高前列腺素E2 (PGE2) 水平以促进组织再生. 这项研究使用基于结构的设计和计算方法开发了新的15-PGDH抑制剂,验证了它们的治疗潜力.
科学领域:
- 生物化学
- 药理学
- 计算化学
背景情况:
- 前列腺素E2 (PGE2) 对于免疫细胞功能和组织再生至关重要.
- 这使得其抑制成为治疗标.
研究的目的:
- 用小分子抑制剂解决15-PGDH的第一个共晶结构.
- 使用基于结构的方法和计算工具合理设计新的15-PGDH抑制剂.
- 通过15-PGDH抑制提高PGE2水平的治疗假设.
主要方法:
- 用小分子抑制剂对15-PGDH进行共结晶.
- 基于结构的药物设计.
- 先进的计算方法包括自由能量扰动 (FEP+) 和WaterMap.
- 机器学习 (ML) 模型开发以指导合成优先级.
- 在小鼠体内给药 (IP),以测量结肠PGE2水平.
主要成果:
- 确定了第一个与抑制剂结合的15-PGDH的共晶结构.
- 通过理性设计和计算建模开发了新的15-PGDH抑制剂系列.
- 一个机器学习模型有效地指导了合成化合物的优先级.
- 一种化合物在给药后成功提高了小鼠的结肠PGE2水平.
结论:
- 基于结构的设计和计算方法对于开发强效的15-PGDH抑制剂是有效的.
- 抑制15-PGDH是一种可行的提高PGE2水平的策略.
- 开发的化合物对受益于增强PGE2信号的疾病具有治疗潜力.
更多相关视频
13:35Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
586
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.5K
相关概念视频
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Prodrugs
2.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.8K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K
